摘要
目的观察强化他汀治疗与常规剂量他汀联用地尔硫卓对择期PCI术中无复流及血清HDL-C、LDL-C、hs-CRP的影响。方法选择70例择期PCI患者随机分为强化组(n=35)与地尔硫卓组(n=35),强化组术前2天予阿托伐他汀80 mg/d,40 mg/d服用1个月。后20 mg/d长期服用。地尔硫卓组术前2天予地尔硫卓90 mg/d,阿托伐他汀20 mg/d预处理,术后长期服用。分别检测术前,术后1月,3月血浆HDL-C、LDL-C及hs-CRP水平及CTFC帧数并观察两组术中无复流的发生率,终点事件是30天内的MACE事件。结果两组均未出现MACE。术后3月两组HDL-C均上升,LDL-C均下降,强化组变化更明显(P<0.05)。两组hs-CRP较术前均有下降(P<0.05),但组间差异无统计学意义。术后1月CTFC帧数强化组下降明显(P<0.05),地尔硫卓组差异无统计学意义。无复流发生率两组间无差异。结论强化他汀治疗能够降低择期PCI患者血浆hs-CRP水平并减少术后1月CTFC帧数。
Objective To investigate the effects of intensive atorvastatin therapy and atorvastatin combined diltiazem therapy in patients with no reflow after elective percutaneous coronary intervention （ PCI ）. Methods Seventy patients undergoing elective PCI were randomly divided into intensive atorvastatin therapy group （35 patients ） and routine atorvastatin combined dihiazem therapy group （35 patients）. The patients in the intensive atorvastatin group were given atorvastatin 80 mg/d for 2days before PCI and followed by 40 mg/day for 50 days after PCI. Patients in the other group were given atorvastatin 20 mg/day and diltiazem 90 mg/day for 2 days before PCI and was taken for long periods. CTFC and plasma HDL-C, LDL-C, hs-CRP were tested in the two groups before as well as 1 and 3 months after PCI. The patients with no-reflow were recorded. The 30-day incidence of major adverse cardiac events （ MACE ）. Results NO occurrence of MACE were found in both groups. Plasma HDL-C significantly increased and LDL-C decreased in the intensive group compared with those in the routine atorvastatin combined dihiazem group after 3 months （ P 〈 0.05 ）. Plasma hs-CRP decreased in the two groups after 3 months （ P 〈 0.05 ） . But there was no statistical significance between the two groups. The incidence of no-reflow was 3/35 in the two groups with no statistical significance between groups. Conclusions Intensive atorvastatin therapy can decreases plasma hs-CRP level and CTFC.
出处
《齐齐哈尔医学院学报》
2013年第22期3328-3329,共2页
Journal of Qiqihar Medical University
关键词
强化他汀治疗
经皮冠状动脉介入治疗
无复流
地尔硫卓
超敏C反应蛋白
Intensive atorvastatin therapy
Percutaneous coronary intervention
No-reflow
diltiazem
High sensitive C reaction protein
